Literature DB >> 7669559

Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry.

N Feller1, C M Kuiper, J Lankelma, J K Ruhdal, R J Scheper, H M Pinedo, H J Broxterman.   

Abstract

Multidrug resistance (MDR) in tumour cells is often caused by the overexpression of the plasma membrane drug transporter P-glycoprotein (P-gp) or the recently discovered multidrug resistance-associated protein (MRP). In this study we investigated the specificity and sensitivity of the fluorescent probes rhodamine 123 (R123), daunorubicin (DNR) and calcein acetoxymethyl ester (calcein-AM) in order to detect the function of the drug transporters P-gp and MRP, using flow cytometry. The effects of modulators on the accumulation and retention of these probes were compared in several pairs of sensitive and P-gp- as well as MRP-overexpressing cell lines. R123, in combination with the modulator PSC833, provided the most sensitive test for detecting P-gp-mediated resistance. Moreover, in a 60 min drug accumulation assay R123 can be regarded as a P-gp-specific probe, since R123 is not very efficiently effluxed by MRP. In contrast to R123, a 60 min DNR or calcein-AM accumulation test could be used to detect MRP-mediated resistance. The MRP-specific modulator genistein could be used in combination with DNR, but not with calcein-AM. Vincristine (VCR) can be used to increase the cellular uptake of calcein-AM in MDR cells, but is not specific for MRP. Thus, although the combination of DNR with genistein appeared to be as sensitive as the combination of calcein-AM with VCR, the former may be used to probe specific MRP activity whereas the latter provides a combined (P-gp + MRP) functional MDR parameter. With these functional assays the role and relative importance of P-gp and MRP can be studied in, for example, haematological malignancies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669559      PMCID: PMC2033905          DOI: 10.1038/bjc.1995.371

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance.

Authors:  C H Versantvoort; S Withoff; H J Broxterman; C M Kuiper; R J Scheper; N H Mulder; E G de Vries
Journal:  Int J Cancer       Date:  1995-05-04       Impact factor: 7.396

2.  The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.

Authors:  G J Zaman; M J Flens; M R van Leusden; M de Haas; H S Mülder; J Lankelma; H M Pinedo; R J Scheper; F Baas; H J Broxterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

3.  ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein.

Authors:  G Jedlitschky; I Leier; U Buchholz; M Center; D Keppler
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

4.  A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes.

Authors:  P R Twentyman; T Rhodes; S Rayner
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

5.  Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells.

Authors:  H S Mülder; J Lankelma; H Dekker; H J Broxterman; H M Pinedo
Journal:  Int J Cancer       Date:  1994-10-15       Impact factor: 7.396

6.  Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.

Authors:  H Burger; K Nooter; G J Zaman; P Sonneveld; K E van Wingerden; R G Oostrum; G Stoter
Journal:  Leukemia       Date:  1994-06       Impact factor: 11.528

7.  Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications.

Authors:  B J Kuss; R G Deeley; S P Cole; C L Willman; K J Kopecky; S R Wolman; H J Eyre; S A Lane; J K Nancarrow; S A Whitmore
Journal:  Lancet       Date:  1994-06-18       Impact factor: 79.321

8.  Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies.

Authors:  M J Flens; M A Izquierdo; G L Scheffer; J M Fritz; C J Meijer; R J Scheper; G J Zaman
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

9.  Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.

Authors:  G J Schuurhuis; H J Broxterman; G J Ossenkoppele; J P Baak; C A Eekman; C M Kuiper; N Feller; T H van Heijningen; E Klumper; R Pieters
Journal:  Clin Cancer Res       Date:  1995-01       Impact factor: 12.531

10.  Calcein accumulation as a fluorometric functional assay of the multidrug transporter.

Authors:  Z Holló; L Homolya; C W Davis; B Sarkadi
Journal:  Biochim Biophys Acta       Date:  1994-05-11
View more
  21 in total

Review 1.  Diagnostics of multidrug resistance in cancer.

Authors:  G Szakács; K Jakab; F Antal; B Sarkadi
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

2.  Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells.

Authors:  Xiao-Ping Chen; Qi Wang; Jian Guan; Zhi-Yong Huang; Wan-Guang Zhang; Bi-Xiang Zhang
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  Rapid detection of ABC transporter interaction: potential utility in pharmacology.

Authors:  Robert W Robey; Bo Lin; Jean Qiu; Leo Li-Ying Chan; Susan E Bates
Journal:  J Pharmacol Toxicol Methods       Date:  2010-11-25       Impact factor: 1.950

4.  Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells.

Authors:  K Terashi; M Oka; H Soda; M Fukuda; S Kawabata; K Nakatomi; K Shiozawa; T Nakamura; K Tsukamoto; Y Noguchi; M Suenaga; C Tei; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance.

Authors:  Tamami Seo; Yoshimasa Urasaki; Takanori Ueda
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

Review 6.  Flow cytometric evaluation of multidrug resistance proteins.

Authors:  Adorjan Aszalos; Barbara J Taylor
Journal:  Methods Mol Biol       Date:  2010

7.  Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.

Authors:  R V Srinivas; D Middlemas; P Flynn; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

8.  Assessment of multidrug resistance on cell coculture patterns using scanning electrochemical microscopy.

Authors:  Sabine Kuss; David Polcari; Matthias Geissler; Daniel Brassard; Janine Mauzeroll
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-17       Impact factor: 11.205

9.  Kinetic analysis of rhodamines efflux mediated by the multidrug resistance protein (MRP1).

Authors:  Chantarawan Saengkhae; Chatchanok Loetchutinat; Arlette Garnier-Suillerot
Journal:  Biophys J       Date:  2003-09       Impact factor: 4.033

10.  Reversal of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR by LY980503.

Authors:  Da-Long Wu; Ying Xu; Li-Xin Yin; Huan-Zhang Lu
Journal:  World J Gastroenterol       Date:  2007-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.